Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Revenue (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Revenue for 1 consecutive years, with -$13267.0 as the latest value for Q2 2025.

  • On a quarterly basis, Revenue changed N/A to -$13267.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $15.0 million, a N/A change, with the full-year FY2025 number at $15.6 million, changed N/A from a year prior.
  • Revenue was -$13267.0 for Q2 2025 at Neuphoria Therapeutics, down from $15.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $15.0 million in Q1 2025 to a low of -$13267.0 in Q2 2025.